Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKN003 vs T-DM1 in HER2-Positive Advanced Breast Cancer
NCT06846437Phase 3Recruiting
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Feb 2025
- Primary completion
- Oct 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of anbenitamab repodatecan in HER2-positive breast cancer, sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started Feb 2025; status: recruiting.
02
Drugs
anbenitamab repodatecan
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT06846437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06846437.